Home
About
Overview
Sharing Data
ORCID
Help
History (13)
Wearable Technology and How This Can Be Implemented into Clinical Practice.
Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study.
Conventional treatment in inflammatory bowel disease--recent trends. Immunosuppressants and biologic agents: should they or need they be used together? How to use immunosuppressive therapy better (and safer) tomorrow?
Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin.
Relating pathogenic loss-of-function mutations in humans to their evolutionary fitness costs.
See All 13 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Relating pathogenic loss-of-function mutations in humans to their evolutionary fitness costs.
Relating pathogenic loss-of-function mutations in humans to their evolutionary fitness costs. Elife. 2023 01 17; 12.
View in:
PubMed
subject areas
Autistic Disorder
Case-Control Studies
Female
Humans
Loss of Function Mutation
Male
Mutation
Phenotype
authors with profiles
Molly Przeworski